Introduction
Nonprescription (over-the-counter, OTC) cough and cold medications are frequently used in the treatment of upper respiratory tract infections and in the treatment of allergic diseases despite recent data that these medications have not been proved to be effective in treating cough and cold symptoms in young children. 1 A survey conducted from 1999 to 2006 among participants aged 0 to 17 years old revealed that in a given week 10.1% of US children use OTC cough and cold products. The class most often used was decongestants such as pseudoephedrine (6.1%) followed by first-generation antihistamines such as diphenhydramine (6.3%). Combination products accounted for 64.2% of all cough and cold medications used. 2 Concerns for toxicities associated with the use of these products have been a popular topic of discussion in recent years. There are a wide variety of rare but serious side effects associated with the use of these products, including convulsions, death, rapid heart rate, and acute mental status changes. 3 In 2004, The Toxic Exposure Surveillance System documented nearly 90 000 calls and 3 accidental deaths associated with the use of OTC cough and cold products among US children. 4 The Centers for Disease Control and Prevention linked these medications to more than 1500 emergency department visits in 2004-2005. 5 In another study, a panel of experts reviewed all reported pediatric fatalities from The National Poison Database System of the American Association of Poison Control Centers, Adverse Event Reports submitted to the major manufacturers of nonprescription cough and cold products, the Food and Drug Administration (FDA) briefing materials for its advisory committee meeting on October 18-19, 2007, a Citizen Petition to the FDA submitted on March 1, 2007 , and the general medical literature, and they found a total of 189 US deaths in children younger than 12 years. It was concluded that 118 of those cases were possibly related to the use of nonprescription cough and cold medications. 3 These concerns prompted an FDA review of the safety and efficacy of OTC cough and cold medications for children. In January 2008, the US FDA issued a Public Health Advisory for patients and caregivers, recommending against the use of OTC cough and cold medications in children and infants younger than 2 years. Charles Ganley, MD, director of the FDA's Office of Nonprescription Products, stated that "these medicines, which treat symptoms and not the underlying conditions, have not been shown to be safe or effective in children under two." 6 To analyze our local patterns of medication use and compliance with the FDA recommendations, a quality assurance project was performed.
Objective
On January 17, 2007, the FDA issued a public health advisory recommending that the use of OTC cough and cold medications be avoided in children younger than 2 years. We performed a systemwide quality assurance project to evaluate the compliance of prescribing health care providers with this public health advisory. Our primary focus was on ensuring compliance within our hosting department, the Department of Emergency Medicine (ED). Secondary processes studied included the compliance of non-ED practitioners within our system. The local health care system within the Department of Defense (DOD) represents a unique opportunity to study this quality of care issue as medications typically considered OTC in the non-DOD setting are very frequently placed via the medical computer system as prescriptions within the local pharmacies. This allows a cross-sectional analysis of this issue, which is not possible in many other health care systems.
Materials and Methods
Outpatient prescription information for prescriptions written and dispensed to patients younger than 2 years between 1 February, 2007, and 31 July, 2007, and 1 February, 2008, and 31 July, 2008 (months subsequent to the statement by the FDA and American Academy of Pediatrics), were collected and compiled from the DOD order processing database. Data were collected via a search query that pulled data regarding prescriptions for patients who during the specified date range were younger than 2 years as indicated by their date of birth (ie, for the period 1 February, 2007, to 31 July, 2007, data included in the query were for patients whose date of birth was 1 February, 2005, or later). These prescription data were then filtered down to include only prescriptions written for the following American Hospital Formulary Service therapeutic classes: (1) nonnarcotic antitussives and expectorants, and (2) sympathomimetic agents.
The data were then manually sorted to ensure that only OTC cough and cold medications were included. The final data contained only prescription information for guaifenesin, dextromethorphan or combinations (eg, Robitussin-DM), and pseudoephedrine. Data collected included patient's date of birth, medication prescribed, American Hospital Formulary Service therapeutic classification, and the originating location of the prescriber. All provider and patient identification information was excluded from the data collection. Prescriptions placed for OTC cough and cold medications in children younger than 2 years were examined based on location of origin as were total prescriptions placed for all medications in children of that age during the same time period. A breakdown by clinics was provided to each clinic as part of this quality assurance project.
Prior to conducting this project, the proposal was reviewed by the Department of Clinical Investigations, which deemed this project as process improvement and quality assurance.
Results
Before the release of the FDA public health advisory recommending that the use of OTC cough and cold medications be avoided in children younger than 2 years, prescription data from 1 February, 2007, to 31 July, 2007, revealed that 1.5% of all prescriptions generated by ED providers and issued to children younger than 2 years were written for OTC cough and cold medications. This percentage of prescriptions was slightly lower then the average for all local DOD military treatment facilities, which was 2.35%. Family medicine and primary care clinics prescribed these medications in 3.1% of all prescriptions for children younger than 2 years. Pediatrics and pediatric subspecialties prescribed these 2.24% of the time (see Table 1 ). Following the FDA's statement, from 1 February, 2008, to 31 July, 2008, the percentage of prescriptions written for OTC cough and cold medications from the emergency department in the same patient population fell to 0.2%, which was below the Oahu military treatment facility average of 1.07%. Both pediatrics and family medicine decreased prescriptions for these medications as well to 1.33% and 0.5%, respectively (see Table 2 ). 
Discussion
The FDA advisory statement against the use of OTC cough and cold medications in children younger than 2 years was released in January 2008 in response to a citizen petition submitted to the FDA on March 1, 2007, which expressed concern regarding present knowledge that there are very limited data from clinical trials showing the efficacy of this class of medications in the reduction of cold symptoms in children. The FDA had also become increasingly aware of cases of serious adverse events, including death in rare cases, which were associated with the use of these products. In January 2007, the Centers for Disease Control and Prevention published a report describing 3 infants who died after using OTC cough and cold products. In February 2007, the FDA completed an internal review in which there were 54 reported deaths associated with the use of decongestants and 69 deaths associated with antihistamines between 1969 and 2006 in children younger than 6 years, the majority of cases occurring in children younger than 2 years. 5, 6 Furthermore, because adverse event reporting is not required for monograph products, there is no way of delineating the true incidents of adverse events related to the use of the OTC cough and cold products. 7 However, with reports of unexpected childhood and infant deaths published from various sources, this has reasonably become an area of concern. 3,4,8 Despite the FDA's recommendation, a poll performed by National Public Radio reported that 20% of parents with children younger than 2 years still planned to use these medications for the relief of symptoms in their children. 9 The compliance of providers with this statement has been difficult to assess as providers may often recommend the use of these products to parents without issuing a formal prescription. Sales data from local pharmacies or convenience stores only provide estimates of their use in the general population and provide no insight into the use of these products in a specific population of patients younger than 2 years.
The military system provides a unique environment in which to study the prescriptive habits of providers as they relate to the use of OTC cough and cold medications in children and their compliance with the FDA and American Academy of Pediatrics advisory statements discouraging their use. In contrast to the civilian setting where providers seldom prescribe OTC medications but instead instruct their patients to purchase such products at their local pharmacy or convenience store, patients within the military system have all their standard medication costs fully covered by their military benefits and are therefore very often prescribed OTC products to avoid having any out-ofpocket costs that they would incur from purchasing these products at their local pharmacy. This unique characteristic allows us to obtain an accurate picture of provider compliance with the FDA advisory statement. In the civilian setting, it would be extremely difficult to obtain an estimation of the number of providers recommending their use. In the military setting, it is a reasonable assumption that providers who are recommending the use of these products will also be entering prescriptions that will be captured in the data collection for this quality assurance project.
Limitations
This quality assurance/process improvement review has several limitations. Primarily, this manuscript is a descriptive analysis of prescriptive practice within a geographically limited population within a closed health care system. Second, there is no "gold standard" for a prescriptive frequency for these medications that defines "reasonable use." One study demonstrated a 10.1% use of these medications by children in any given week. 2 Additionally, it is likely that different clinics and the emergency department innately have a somewhat different patient mix. Specifically, complaints of cough and cold symptoms are likely to be more common complaints at clinics than at the ED, thus, making the use of medications purported to treat these symptoms likely to be more common. Antihistamines were purposely excluded from this project because there exist some reasonable indications for their occasional use in this age group, and without reviewing each case, it would be extremely challenging to define appropriate use. Finally, it is not possible to account for possible "doctor recommendations" for the use of these medications. Although we believe that within our system health care providers most frequently enter an OTC prescription, it is possible that some health care providers recommend that parents purchase these items at the store.
Conclusion
Prior to the release of the FDA advisory statement regarding the use of OTC cough and cold medications in children younger than 2 years, providers impaneled to the Department of Emergency Medicine seldom prescribed these classes of medications to children younger than 2 years. Following the FDA's advisory statement, the use of these medications in this particular patient population fell even further to 0.2% of all prescriptions written for children younger than 2 years. Overall, the prescription of these medications decreased among all groups of providers subsequent to the FDA statement. Furthermore, on average, ED-dedicated providers appeared to use these medications less frequently than average across all local military treatment facilities. These data support the compliance of local providers with current standards and recommendations issued by the FDA regarding the use of OTC cough and cold medications in young children. This topic is a valuable one to include in continuing education curricula for all providers caring for young children.
